An interventional study of TetraGraph in Surgery, sponsored by Joseph D. Tobias. Completed at 1 site in United States. Open to participants aged 28 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Joseph D. Tobias · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective, non-blinded study to evaluate rocuronium infusion requirements using the TetraGraph Neuromuscular Transmission Monitor during surgical procedures in patients less than 18 yrs. of age.
Joseph D. Tobias is the lead sponsor of 28 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are scheduled for elective, urgent or emergent surgery requiring the continuous infusion of the neuromuscular blocking agent, rocuronium.
Device: TetraGraph
etraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
Rocuronium Bolus Dose
Amount of rocuronium administered in a bolus dose during induction of anesthesia.
Time frame: During the surgery (2-8 hrs.)
Rocuronium Infusion Dose
The amount of rocuronium given by continuous infusion in mg/kg/hr to maintain one twitch of the train of four (TOF)
Time frame: During surgery (2-8 hrs.)
Maximum Dose of Rocuronium
The maximum dose of rocuronium administered by a continuous infusion per patient to maintain one twitch of the train of four (TOF)
Time frame: During the surgery (2-8 hrs.)
Rocuronium Infusion Time
Amount of time in minutes that patients received rocuronium infusion.
Time frame: During the surgery (2-8 hrs.)
Rocuronium Rescue Boluses
The number of patient that received rescue boluses of rocuronium in addition to the infusion to maintain one twitch of the train of four (TOF)
Time frame: During the surgery (2-8 hrs.)
Anesthesia Time
The total amount of time patients were under anesthesia care in minutes.
Time frame: During the surgery (2-8 hrs.)
Surgical Time
The total amount of time from first incision to closure in minutes.
Time frame: During the surgery (2-8 hrs.)
| Milestone | Rocuronium Infusion |
|---|---|
| Started | 50 |
| Completed | 48 |
| Not completed | 2 |
| Withdrew: Surgical procedure canceled | 1 |
| Withdrew: Physician decision | 1 |
Amount of rocuronium administered in a bolus dose during induction of anesthesia.
| mg/kg | Rocuronium Infusion |
|---|---|
| Rocuronium Bolus Dose | 0.8 (0.7 to 1.1) |
The amount of rocuronium given by continuous infusion in mg/kg/hr to maintain one twitch of the train of four (TOF)
| mg/kg/hr | Rocuronium Infusion |
|---|---|
| Rocuronium Infusion Dose | 0.48 (0.36 to 0.6) |
The maximum dose of rocuronium administered by a continuous infusion per patient to maintain one twitch of the train of four (TOF)
| Participants | Rocuronium Infusion |
|---|---|
| 0.1 to <0.4 mg/kg/hr | 1 |
| 0.4 to 0.6 mg/kg/hr | 41 |
| >0.6 to 0.72 mg/kg/hr | 6 |
Amount of time in minutes that patients received rocuronium infusion.
| minutes | Rocuronium Infusion |
|---|---|
| Rocuronium Infusion Time | 201.5 (138.5 to 310) |
The number of patient that received rescue boluses of rocuronium in addition to the infusion to maintain one twitch of the train of four (TOF)
| Participants | Rocuronium Infusion |
|---|---|
| Rocuronium Rescue Boluses | 26 |
The total amount of time patients were under anesthesia care in minutes.
| minutes | Rocuronium Infusion |
|---|---|
| Anesthesia Time | 339 (250 to 445.5) |
The total amount of time from first incision to closure in minutes.
| minutes | Rocuronium Infusion |
|---|---|
| Surgical Time | 225 (178 to 313) |
Collected over 1 Day (day of surgery). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rocuronium Infusion | 0/48 (0%) | 0/48 (0%) | 0/48 (0%) |
| Age, Categorical(Participants) | Rocuronium Infusion |
|---|---|
| <=18 years | 48 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | Rocuronium Infusion |
|---|---|
| Median | 13 (8 to 16) |
| Sex: Female, Male(Participants) | Rocuronium Infusion |
|---|---|
| Female | 15 |
| Male | 33 |
| Ethnicity (NIH/OMB)(Participants) | Rocuronium Infusion |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 47 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Rocuronium Infusion |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 38 |
| More than one race | 5 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Rocuronium Infusion |
|---|---|
| United States | 48 |
| Height(centimeters) | Rocuronium Infusion |
|---|---|
| Median | 156.6 (125.4 to 173) |
| Weight(kilograms) | Rocuronium Infusion |
|---|---|
| Median | 55.9 (29.5 to 69.3) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2024 to primary completion in Apr 2025, 7 months.
Results were first posted in May 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joseph D. Tobias